Cat. #151428
Anti-CD86 [BU63] mAb
Cat. #: 151428
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: CD86
Class: Monoclonal
Application: FACS ; IHC ; IF ; IP ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: University of Birmingham
Primary Citation: Engel et al. 1994. Blood. 84(5):1402-7. PMID: 7520767.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD86 [BU63] mAb
- Alternate name: B7.2
- Research fields: Cell biology;Immunology;Stem cell biology
- Clone: BU63
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IF ; IP ; WB
- Description: Monoclonal antibody directed against CD86 glycoprotein, without impacting on CTLA-4 activity. It aids the investigation of the adaptive immune response system.
- Immunogen: ARH 77 (B-lymphoblastoid cell line)
- Immunogen uniprot id: P42081
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: CD86
- Target background: CD86 is a 70 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors. CD86 was established during the 5th International Leukocyte Differentiation Antigen Workshop. CD86 is expressed on resting monocytes and dendritic cells, activated T and Natural Killer cells. CD86 rapidly induced on the surface of activated B-cells and is the ligand for two different proteins on the T cell surface: CD28, for autoregulation and intercellular association, and CTLA-4, for attenuation of regulation and cellular disassociation. CD86 works in tandem with CD80 to prime T cells in the primary immune response. CD86 is also expressed by malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease. Anti-CD86 BU63, alongside another monoclonal antibody, helped define CD86 single-chain cell-surface protein expressed by blood monocytes and activated B cells. This antibody does not block CTLA-4 binding to B7-2/B70, but induces a conformational change in CD86 which increases the binding affinity of soluble CTLA-4.
Applications
- Application: FACS ; IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Dry ice
References
- Santos et al. 2019. Immunology. 157(4):296-303. PMID: 31162836.
- Jeffery et al. 2015. PLoS One. 10(7):e0131539. PMID: 26134669.
- Means et al. 2007. J Virol. 81(12):6573-83. PMID: 17409151.
- Gigure et al. 2004. J Virol. 78(12):6222-32. PMID: 15163715.
- O'Sullivan et al. 2002. J Immunol. 168(11):5491-8. PMID: 12023343.
- Latour et al. 2001. J Immunol. 167(5):2547-54. PMID: 11509594.
- Mauri et al. 1995. J Immunol. 155(1):118-27. PMID: 7541409.
- Schlossman SF et al. 1995. Leucocyte Typing V Oxford University Press.
- Caux et al. 1994. J Exp Med. 180(5):1841-7. PMID: 7525840.
- Engel et al. 1994. Blood. 84(5):1402-7. PMID: 7520767.
- Nozawa et al. 1993. J Pathol. 169(3):309-15. PMID: 8492223.
